LTP·01learntopeptide
OtherPeptideEvidence C4 cited

DSIP

Delta Sleep-Inducing Peptide

aka Delta Sleep Inducing Peptide · DSIP · Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

A naturally occurring neuropeptide researched for its role in promoting delta wave sleep and circadian regulation.

Molecular wt
848.8g/mol
Formula
C35H48N10O15
CAS
62568-57-4
Half-life
8 min
clinical
Tmax
15 min
Route
Subcutaneous injection
PubChem
68816

Sequence

One-letter9 residues

WAGGDASGE

Three-letter

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Read this before quoting the sequence
Delta sleep-inducing peptide, a linear nonapeptide with a free C-terminal glutamic acid. INN: emideltide. PubChem systematic synonym for CID 68816: 'L-Glutamic acid, L-tryptophyl-L-alanylglycylglycyl-L-alpha-aspartyl-L-alanyl-L-serylglycyl-'.
Source ↗

Mechanism of action

Delta sleep-inducing peptide (DSIP) is thought to interact with the central nervous system by modulating the activity of neurotransmitters such as serotonin and norepinephrine. It may influence the sleep-wake cycle by promoting delta wave sleep, which is crucial for restorative sleep. DSIP is also believed to have a role in regulating the body's stress response by affecting the hypothalamic-pituitary-adrenal axis.

What the evidence actually shows

Grade C

There are limited human trials on DSIP, with most studies being small and preliminary. Some trials suggest improvements in sleep quality and stress reduction, but results are inconsistent. More robust, large-scale studies are needed to confirm these effects.

Regulatory status

Status
Not approved as a medicine in any jurisdiction identified. No entry in Drugs@FDA or the EMA medicines register. Holds an INN (emideltide) but that confers no approval.
Clinical stage
Small uncontrolled human pilot studies in the 1980s (Larbig 1984); no modern registered controlled trials identified.
WADA
Not named on the WADA 2026 Prohibited List. S0 (Non-Approved Substances) prohibits at all times 'any pharmacological substance ... with no current approval by any governmental regulatory health authority for human therapeutic use', which on its face covers DSIP.
UK
research_compound

In the UK, DSIP is not approved for medical use and is considered a research compound.

Source ↗

Pharmacokinetics

Half-life
8 min
Tmax
15 min
Absorption
subcutaneous
Elimination
renal
Washout
1 days
Low-confidence pharmacokinetics
These figures are recorded as clinical rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Dosing — what backs each figure

DSIP was tested in humans in the 1980s-2000s, but only by intravenous bolus in nmol/kg (25-100 nmol/kg) for insomnia and as an anaesthesia adjunct, and intranasally at 300 microg/day in Russian ophthalmology work; the insomnia trial concluded the sleep improvement was 'of little clinical significance'. There is no established human dose, no modern trial, and no published subcutaneous bedtime regimen.

ClinicalApproved labelling or a published human trial
PreclinicalAnimal studies — not a human dose

  • i.c.v., i.v. and s.c. administration produced a parabolic (non-monotonic) dose-response curve with different effective optima by route - higher doses were not more effective

    rabbit, rat, cat · intracerebroventricular / intravenous / subcutaneous · PMID 6548966

Animal doses do not convert to human doses by body weight alone. Route matters too — a compound dosed intraperitoneally in mice tells you little about subcutaneous use.

Commonly circulatedNot established by any study
Dose
Research literature cites ~100 to 300 mcg at night
Frequency
Before bed

Why this isn't evidence
No published human study used subcutaneous DSIP at 100-300 microg before bed: the sleep and anaesthesia trials used intravenous doses of 25-100 nmol/kg (roughly 1.5-6 mg for a 70 kg adult, i.e. an order of magnitude higher), and the only study that used ~300 microg gave it intranasally for diabetic retinopathy, not for sleep.

This figure is shown because it is what circulates and what people search for — not because it is supported. Cycle lengths in particular tend to be convention copied between compounds rather than anything derived from a compound's own pharmacokinetics.

Handling and storage

No compound-specific stability data exists
No compound-specific storage data exists in any regulatory label, pharmacopoeia or published stability study that could be retrieved. DSIP has no marketing authorisation. Only generic lyophilised-peptide handling guidance would apply. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

Commonly reported
  • ·Drowsiness
  • ·Headache
Rarely reported
  • ·Allergic reactions
  • ·Mood changes
Contraindications
  • ·Pregnancy
  • ·Breastfeeding
  • ·"Severe psychiatric disorders"
Drug interactions
  • ·Sedatives: May enhance sedative effects due to CNS modulation

Limited data; generally well tolerated

Reported combinations

Reported as synergistic
  • ·Melatonin
  • ·Magnesium
Reported as antagonistic
  • ·Stimulants like caffeine

Combination claims in this dataset are largely unsourced and should be treated as folk knowledge until a citation appears beside them.

References (4)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
storage, reconstitution

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Other

AHK-Cu
A synthetic copper tripeptide analogue of GHK-Cu, researched for collagen synthesis and skin regeneration.
Apelin
A peptide ligand for the APJ receptor (APLNR) with potent cardiovascular, metabolic, and anti-aging effects. Apelin levels decline with aging and are reduced in cardiovascular disease.
Argireline
A topical hexapeptide that modulates the SNAP-25 protein complex to reduce expression lines. Functions as a topical alternative to botulinum toxin with a milder, non-paralytic mechanism.